Capital News

Autosomal Dominant Polycystic Kidney Disease Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

Autosomal Dominant Polycystic Kidney Disease Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

October 06
17:07 2022
Autosomal Dominant Polycystic Kidney Disease Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
Autosomal Dominant Polycystic Kidney Disease Market
DelveInsight’s ‘Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as Autosomal Dominant Polycystic Kidney Disease trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan

DelveInsight’s ‘Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as Autosomal Dominant Polycystic Kidney Disease trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan

 

The Autosomal Dominant Polycystic Kidney Disease market report provides current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted 7MM Autosomal Dominant Polycystic Kidney Disease market size from 2019–2032. The report also covers current Autosomal Dominant Polycystic Kidney Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Some of the key facts of the Autosomal Dominant Polycystic Kidney Disease Market:

  • According to a Hospital-based nationwide survey in Japan, it has been found that the prevalence of ADPKD increased with age and reached a peak value of 261 per million population in the age group of 55-59 years.  The probability of end-stage renal disease is at most 50% among ADPKD patients (Higashihara, 1998).
  • Mutations in either the PKD1 or PKD2 gene can cause ADPKD, PKD1 and PKD2 encode polycystin 1 and polycystin 2 and approximately 1 in 1000 people bear a mutation in either PKD1 or PKD2 genes worldwide. 

Got queries? Click here to know more about the Autosomal Dominant Polycystic Kidney Disease Market Landscape 

Autosomal Dominant Polycystic Kidney Disease Overview 

Autosomal Dominant Polycystic Kidney Disease is a genetic disorder that causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. Renal manifestations are produced by the progressive and continuous enlargement and proliferation of fluid-filled cysts, leading to enlargement of the kidney up to five times the normal volume in the years prior to the development of kidney failure.

Autosomal Dominant Polycystic Kidney Disease may lead to the development of end-stage renal disease (ESRD) and is the fourth most common renal disease requiring renal replacement therapy (RRT). The most common extra-renal manifestation is a polycystic liver disease (PLD), which is more common in women than in men.The most common symptoms are kidney cysts, pain in the back and the sides and headaches. Other symptoms include liver and pancreatic cysts, urinary tract infections, abnormal heart valves, high blood pressure, kidney stones, and brain aneurysms.

 Autosomal Dominant Polycystic Kidney Disease Epidemiological Insight:

 

  • According to an epidemiological review of ADPKD in the EU, a minimum prevalence of 2.41 and 3.89 per 10,000, and a screening prevalence of 3.3 and 4.6 per 10,000 of Autosomal Dominant Polycystic Kidney Disease have been found in the German and British Population-based studies. Whereas in the registry-derived method, the minimum prevalence was 3.29 per 10,000, and if Autosomal Dominant Polycystic Kidney Disease screening was implemented in all European countries, the expected prevalence was 3.96 per 10 000 (Willey, 2017).
  • Autosomal Dominant Polycystic Kidney Disease affects more than 600,000 Americans and 12.4 million people worldwide. About nine out of every 10 people with PKD have the autosomal dominant form. The prevalence of ADPKD is estimated to range from 1 in 400 to 1000 live births, with 5,000–6,000 new cases diagnosed each year (Rashid, 2018). 
  • In the National Ambulatory Medical Care Survey (2013-2015) the diagnosed prevalence of Autosomal Dominant Polycystic Kidney Disease for the US population was found to be 4.3 per 10,000 in the and age-adjusted prevalence rates in the commercial and Medicaid population were 2.06 and 2.28 per 10,000 (Willey,2015).

 Autosomal Dominant Polycystic Kidney Disease Epidemiological Segmentation

  • Autosomal Dominant Polycystic Kidney Disease Total prevelant cases
  • Autosomal Dominant Polycystic Kidney Disease Age specific cases
  • Autosomal Dominant Polycystic Kidney Disease Diagnosed and Treatable cases

Autosomal Dominant Polycystic Kidney Disease Market Outlook 

Autosomal dominant polycystic kidney disease also called “adult PKD” is the most common inherited kidney disorder characterized by the growth of cysts in the kidneys, which eventually leads to kidney failure. A monogenetic disorder, Autosomal Dominant Polycystic Kidney Disease is caused by mutations in either the PKD1 gene found on chromosome 16 or the PKD2 gene found on chromosome 4. Mutations in PKD1 are more common and account for about 85% of all Autosomal Dominant Polycystic Kidney Disease cases. These genes encode for proteins of the polycystin signaling complex, which regulates different signals, including 3’,5’-cyclic adenosine monophosphate (cAMP), mammalian target of rapamycin (mTOR), and epidermal growth factor receptor pathways.

 

There is currently no effective curative treatment for Autosomal Dominant Polycystic Kidney Disease, and most efforts are aimed at mitigating the complications and progression or reducing cyst growth and delaying the eventual progression to kidney failure. Tolvaptan (Jynarque/Jinarc/Samsca), developed by Otsuka Pharmaceuticals, is the only approved drug available globally for treating Autosomal Dominant Polycystic Kidney Disease in adults. It inhibits vasopressin receptors in the kidneys and retards kidney function decline by reducing adenylate cyclase activity in adults at risk of rapidly progressing Autosomal Dominant Polycystic Kidney Disease.

 

Learn more by requesting for sample @Autosomal Dominant Polycystic Kidney Disease Market Landscape

Autosomal Dominant Polycystic Kidney Disease Key Companies  

  • Palladio Biosciences
  • Regulus Therapeutics
  • Galapagos
  • and many more

Autosomal Dominant Polycystic Kidney Disease Key Therapies

  • Lixivaptan
  • RGLS8429
  • GLPG2737
  • And many more

Table of Contents

  • Key Insights 
  • Report Introduction 
  • Executive Summary of Autosomal Dominant Polycystic Kidney Disease Market 
  • Disease Background and Overview
  • Epidemiology and patient population
  • The United States 
  • EU 5
  • Autosomal Dominant Polycystic Kidney Disease Market  Emerging Therapies
  • Autosomal Dominant Polycystic Kidney Disease Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  • Autosomal Dominant Polycystic Kidney Disease Market Report Methodology
  • DelveInsight Capabilities
  • Disclaimer
  • About DelveInsight

Click here to read more about Autosomal Dominant Polycystic Kidney Disease Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

Recent Posts

Chronic Spontaneous Urticaria Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals

Read Full Article

Categories